HDAC3 inhibition combined with anti-PD-1/PD-L1 therapy can significantly improve the efficacy of B-cell lymphoma treatment (Deng et al., 2019). This evidence concerns the gene HDAC3 and B-cell non-Hodgkin lymphoma.